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Abstract From our recent publications, it was found
that the deimmunization method (Dharshanan et al.
(2012) Sci Res Essays 7:2288–2299) should be
applied for the development of humanized anti-C2
monoclonal antibody (H1C2 mAb). However, the
overlapping-PCR mutagenesis procedure used to
insert the variable regions into cloning vectors was
laborious and time-consuming. Additionally, the
expression of H1C2 mAb in NS0 cells was low in
static culture vessels. Therefore H1C2 mAb was
redeveloped by deimmunization method with the
following modifications in order to optimize the
production of H1C2 mAb. First, instead of the
overlapping-PCR mutagenesis procedure, synthetic
DNA coding the variable regions were used to express
the mAb. Second, two expression vectors, pFUSE and
UCOE, were used to express H1C2 mAb in NS0 cells
and CHO cells in order to investigate the combination
that gave the highest number of high producing stable
clones. This will provide the highest chance of finding
clones with the requisite high productivity and stabil-
ity required for manufacturing. We found that
transfection of UCOE in CHO cells generated the
highest number of high producing stable clones. To
our knowledge, this is the first time that H1C2 mAb
has been expressed in CHO cells.
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In a recent publication (Dharshanan et al. 2012), we
reported that the humanized anti-C2 monoclonal
antibody (H1C2 mAb) developed using the deimmu-
nization method in NS0 cells elicited the lowest
immunogenic response in monkeys and therefore was
most suitable for the development of humanized
mAbs. In that paper we used the overlapping-PCR
mutagenesis method to humanize potential immuno-
genic mouse residues. However, with mammalian
cells this method is long and laborious as it frequently
results in undesired mutations.
Mammalian cells, despite having lower yields,
continue to be the system of choice because the other
systems cannot adequately reproduce the post-transla-
tional modifications and glycosylation patterns that may
be important for the tertiary structure of proteins
(Browne and Al-Rubeai 2007). This is a vital factor
because the lack of fidelity can lead to altered protein
stability, lowered affinity to antigen, more rapid clear-
ance rate and increased immunogenicity. These are
major considerations especially if these mAbs are
intended for repeated use as therapeutic agents in
humans (Wurm 2004). Thus, Chinese hamster ovary
(CHO) and NS0 cell lines have been most commonly
used for the production of therapeutic antibodies (Zhu
2011). Nevertheless, the production of therapeutic
proteins in mammalian cells is an expensive process
with long development time (Browne and Al-Rubeai
2007). Hence, in order to increase culture yields and
stability and at the same time decrease the duration for
the development and production of humanized mAbs, it
is crucial to optimize the in vitro mammalian cell
production system.
In this publication, we have explored alternative
methods from our previous paper in order to improve the
chances of obtaining high-producing stable transfecto-
mas that secrete H1C2 mAb more quickly and effi-
ciently thus lowering the cost of production. First, the
time-consuming and laborious overlapping-PCR muta-
genesis procedure was replaced by the use of synthetic
DNAs which were pre-designed to contain all desired
humanized residues in its DNA sequences. Second,
instead of the monocistronic pAH4602 and pAG4622
expression vectors that were employed previously, two
different monocistronic expression vector systems,
pFUSE and UCOE, as well as a bicistronic UCOE
expression vector system were employed. The pFUSE
vectors contain human antibody constant regions, while
the UCOE expression vectors contain ubiquitous chro-
matin opening elements (UCOE) but lack the human
antibody constant regions. Third, in addition to NS0
cells, CHO cells were also transfected with the pFUSE
and UCOE expression vector systems. The results of the
transfections with the different vectors and cell lines
were compared and the combination that was most
efficient in yielding the greatest number of stable
transfectomas secreting high levels of mAbs was chosen
for large-scale production.
Materials and methods
In this publication, various forms of expression
vectors containing synthetic genes were constructed
from pFUSE and UCOE expression vectors (Dhar-
shanan 2012). These vectors were transfected into
NS0 and CHO cells as summarized in Table 1.
Construction of expression vectors with synthetic
genes coding the variable region of HIC2 mAb
Monocistronic pFUSE expression vectors
Monocistronic expression vectors, pFUSE-CHIG-hG1
and pFUSe2-CLIg-hk (Invivogen, San Diego, CA,
USA) which contain the human IgG1 constant regions
and the human kappa constant regions, respectively,
were used to co-express the heavy and the light chains
of H1C2 mAb. In previous experiments (Dharshanan
et al. 2012) the physical DNA coding for the human-
ized variable regions were inserted into the expression
vectors by the overlapping mutagenesis procedure;
however, here the exact synthetic copies of DNA were
designed and ligated into them instead. The physical
DNAs, humanized-VH (hVH) and humanized-VL
(hVL) (Dharshanan et al. 2011a) were substituted with
the corresponding synthetic copies, syn-hVH and syn-
hVL. The resulting recombinant vectors were named
pFUSE-hVH (containing syn-hVH) and pFUSE-hVL
(containing syn-hVL) (Dharshanan 2012).
Monocistronic UCOE expression vectors
Unlike monocistronic pFUSE vectors, the monocistronic
UCOE vector (CET1019AS) (Millipore, Billerica,
626 Cytotechnology (2014) 66:625–633
123
MA, USA) does not contain the human antibody constant
regions. Therefore, in addition to the synthetic DNA
coding the variable region of H1C2 mAb, synthetic DNA
sequences coding the human antibody constant regions
from pFUSE vectors were also designed and inserted.
The synthetic genes designed were designated as follows:
1. syn-hVH-hCHm: this is the gene sequence coding
the humanized heavy region of H1C2 mAb (hVH)
and the human IgG1 constant region of heavy
chain (hCHm)
2. syn-hVL-hCL: this is the synthetic gene sequence
coding the humanized light region of H1C2 mAb
(hVL) and the Ig Kappa constant region (hCL)
The resulting vectors were named pAS-hVL-hCL
(containing syn-hVL-hCL) and pAS-hVH-hCHm
(containing syn-hVH-hCH) (Dharshanan 2012).
Bicistronic UCOE expression vector
Like the monocistronic UCOE vector, the bicistronic
UCOE vector (CET1019AD) (Millipore, USA) does not
contain the human antibody constant regions. There-
fore, the genes for both the light and heavy chains had to
be inserted. Synthetic gene syn-hVL-hCL was used for
the expression of the light chain. However, for the
expression of the heavy chains, syn-hVH-hCHb which
has BstBI and NotI restriction enzyme sequences at the
50 and 30 end, respectively, was used. A sequential
cloning was performed for the ligation of both syn-hVL-
hCL and syn-hVH-hCHb to CET1019AD and the
resulting vector was named pAD-hVL-hCL-hVH-hCH.
Transfection, selection and qualitative ELISA
The transfections of NS0 and CHO cells (both obtained
from the ATCC, Manassas, VA, USA) were performed
using a 6-well plate format and lipofectamine 2000 (cat.
no.: 11668027, Life Technologies, Carlsbad, CA,
USA). NS0 and CHO cells which had been adapted to
serum-free media were used. NS0 cells were grown in
hybridoma-SFM (cat. no.: 12045, Life Technologies,
USA) containing 1 % (v/v) synthechol (cat. no.: S5442,
Sigma-Aldrich, USA) and 1 % (v/v) glutamax (Life
Technologies, USA) while CHO cells were grown in
HyClone SFM4CHO medium (cat. no.: SH30518,
Thermo Scientific, Logan, UT, USA), supplemented
with 1 % (v/v) glutamax.
With monocistronic pFUSE vectors both NS0 and
CHO cells were co-transfected with linearized pFUSE-
VH and pFUSE-VL vectors as well as with unlinea-
rized pFUSE-VH and pFUSE-VL vectors, since the
pFUSE vectors are relatively small. However, with the
monocistronic and bicistronic UCOE vectors, only the
linearized forms were used because UCOE vectors are
relatively large in size. The linearizations of pFUSE-
VH and pFUSE-VL vectors were performed using NotI
restriction enzyme, while pAS-hVL-hCL, pAS-hVH-
hCHm and pAD-hVL-hCL-hVH-hCH vectors were
linearized using I-SceI homing endonuclease enzyme.
For each well, a total of 4.0 lg of vector DNA were
added. Thus for co-transfection, 2.0 lg of each mon-
ocistronic vector were used. Before transfection, each
vector DNA was diluted in 250 ll of Opti-MEM
reduced-serum medium (cat. no.: 51985034, Life
Technologies, USA) using 1.5 ml centrifuge tubes.
Using different 1.5 ml centrifuge tubes, 10 ll of
lipofectamine were diluted into 250 ll of Opti-MEM
reduced-serum medium and incubated at room tem-
perature for 5 min. After that, the diluted vector DNA
and lipofectamine were combined, gently mixed and
incubated at room temperature for a further 20 min.
For transfection, approximately 106 NS0 or CHO
cells were pelleted by centrifugation at 1,000 rpm for
5 min and resuspended in 1 ml of Opti-MEM reduced-
serum medium. The resuspended cells were added into
Table 1 Summary of combinations of vectors used for the expression of H1C2 mAb in NS0 and CHO cells
Cell line Expression vector system used
pFUSE monocistronic vectors UCOE monocistronic vectors UCOE bicistronic vector
NS0 Linearized Linearized Linearized
Unlinearized
CHO Linearized Linearized Linearized
Unlinearized
For pFUSE vectors both linearized and unlinearized vectors were employed whereas for UCOE vectors only linearized vectors
were used
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each well of 6-well plates. Then, 500 ll of the
lipofectamine-DNA complexes were added drop-wise
to the cells in each well and the plates were then
incubated in a 37 C incubator with 5 % CO2 atmo-
sphere for 4 h before the addition of 4 ml of the
respective growth media for NS0 and CHO cells.
For controls (‘‘mock transfections’’) cells were
similarly treated except that no DNA was added to the
Opti-MEM reduced-serum medium. To remove non-
transfected cells, selective media containing specific
antibiotics were added 72 h post-transfection. For
cells transfected with pFUSE vectors, 200 lg/ml of
zeocin (Life Technologies, USA) and 2 lg/ml of
blasticidin (Life Technologies, USA) were added
while for cells transfected with UCOE vectors, 5 lg/ml
of puromycin (Life Technologies, USA) were added.
The antibiotic selections were performed until all
mock transfected NS0 and CHO cells were non-viable.
The viable parental transfectomas were then evaluated
for H1C2 mAb productivity using qualitative ELISA
as described (Dharshanan et al. 2011a). All transfec-
tions were done in triplicate.
Isolation of high producer transfectomas using
ClonePix FL system and characterization of H1C2
mAb
The screening and selection of NS0 and CHO
transfectomas secreting high levels of H1C2 mAb
were done as described in an earlier publication with
minor modifications (Dharshanan 2012). In order to
grow clones from individual separate transfected cells,
50,000 parental transfectoma cells secreting H1C2
mAb were added to 100 ml of semi-solid growth
media. For NS0 transfectomas, the semi-solid growth
media consisted of 90 ml semi-solid medium for
hybridomas/myelomas (cat. no.: K8600, Molecular
Devices, USA), 1 ml of glutamax, 1 ml of anti-human
capture antibody conjugated to fluorescein isothiocy-
anate (FITC) (cat. no.: K8200, Molecular Devices,
Sunnyvale, CA, USA) and 8 ml of sterile water. For
CHO cells, the semi-solid growth medium for CHO
cells (cat. no.: 8712, Molecular Devices, USA) was
used instead. The cells and medium were mixed
vigorously and 2 ml of each mixture were transferred
to each well of 6-well plates (cat. no.: 3516, Sigma
Aldrich, USA). The plates were then incubated at
37 C, 5 % CO2 with high humidity for 14 days.
The transfectomas in semi-solid medium were then
analyzed using the ClonePix FL system and high
producer clones were identified and isolated as
described (Dharshanan et al. 2011a). The isolated
clones were scaled up in static cell culture vessels and
at passage 10, qualitative and quantitative ELISAs
were performed to evaluate the H1C2 mAb produc-
tivity. The functionality of the H1C2 mAbs secreted
were characterized using SW1116 cells, a colorectal
carcinoma cell-line expressing C2-antigen, as
described previously (Dharshanan et al. 2011b).
Results
Construction of expression vectors
Various synthetic genes were inserted into pFUSE and
UCOE vectors which were then transfected into cells
for the expression of H1C2 mAb. A summary of the
recombinant vectors and their theoretical sizes and
actual sizes as determined by gel electrophoresis is
shown in Table 2.
Transfection and expression of H1C2 mAbs
The viability rates of NS0 and CHO cells after
transfection with various vectors are shown in
Table 3. When NS0 cells were transfected with
linearized pFUSE vectors, all 3 groups contained
viable cells (resistant to the antibiotic used in the
selective media). However, with unlinearized pFUSE
vectors only 1 of the 3 groups of NS0 cells transfected
contained viable cells. On the other hand, all three
CHO populations transfected with linearized mono-
cistronic vector and bicistronic UCOE vector con-
tained viable cells after antibiotic selection. However,
no viable cells were obtained for NS0 cells transfected
with UCOE vectors and CHO cells transfected with
pFUSE vectors.
Productivity of H1C2 mAb in NS0 cells using
pFUSE expression vectors
The viable parental NS0 transfectomas generated with
pFUSE vectors were then analyzed for H1C2 mAb
productivity. As shown in Fig. 1, all three parental
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NS0 transfectomas transfected with linearized pFUSE
vector (NS0-pFUSE-M) produced H1C2 mAb. How-
ever, the one viable NS0 transfectoma population
(transfectoma-2) that was transfected with unlinea-
rized pFUSE vectors failed to produce or produced at
low levels despite the fact that the cells were resistant
to the antibiotics used for the selection of the heavy
and light chain of H1C2 mAb.
Productivity of H1C2 mAb in CHO cells using
UCOE expression vectors
The viable parental CHO transfectomas transfected
with UCOE vectors were also analyzed for H1C2 mAb
productivity. From Fig. 1, all the viable cells of the
triplicate transfections with linearized bicistronic
(linearized CHO-UCOE-B) produced substantial
quantities of H1C2 mAb. However, only one of the
three transfections with monocistronic UCOE vectors
(CHO-UCOE-M) produced cells that secreted signif-
icant levels of mAbs, while the other two populations
showed low productivities.
Selection of high H1C2 mAb producing NS0
and CHO transfectomas using ClonePix FL system
All producing transfectoma populations were then
screened using the ClonePix FL system and ranked
according to their sum total fluorescence intensities.
Since the detection antibody (conjugated to FITC)
used was specific to the human Fc region of human
antibody, the total sum of the fluorescence intensity of
each transfectoma would be a measure of the produc-
tion rate of the whole H1C2 mAb. From the dot-blot
data (Fig. 2), it was found that all parental NS0-
pFUSE-M transfectomas (Fig. 2a) were low producers
as their fluorescence intensities were less than 50,000
FU. The sum of total intensity of the highest NS0-
pFUSE-M producer was only 19,898 FU.
On the other hand, more than 90 % of both CHO-
UCOE-M (Fig. 2b) and CHO-UCOE-B transfectomas
(Fig. 2c) had intensities of greater than 50,000 FU,
indicating a higher level of mAb production rate. The
sum total intensities of the highest producer of CHO-
UCOE-M (Fig. 2b) and CHO-UCOE-B (Fig. 2c) were
3,985,878 and 5,357,028 FU, respectively. It was also












pFUSE-hVH syn-hVH (*0.5 kb) ? pFUSE-CHIg-hG1 (*4.5 kb) *5.0 *5.0
pFUSe2-
CLIg-hk
pFUSE-hVL syn-hVL (*0.4) ? pFUSe2-CLIg-hk (*3.8) *4.2 *4.2
Monocistronic UCOE
CET1019AS pAS-hVH-hCHm syn-hVH-hCHm (*1.5 kb) ? CET1019AS (*8.1 kb) *9.6 *9.6




syn-hVL-hCL (*0.7 kb) ? syn-hVH-hCHb
(*1.5 kb) ? CET1019AD (*11.0 kb)
*13.2 *13.2
For UCOE vectors both monocistronic and bicistronic vectors were employed whereas for pFUSE vectors only monocistronic vectors
were used




Number of viable transfectomas
(out of 3 transfections)
NS0 CHO
Linearized pFUSE-M 3 0
Unlinearized pFUSE-M 1 0
Linearized pUCOE-M 0 3
Linearized pUCOE-B 0 3
For the selection of stable transfectomas, zeocin and blasticidin
were used for cells transfected with pFUSE vectors, while
puromycin was used for cells transfected with UCOE vectors.
All transfections were performed in triplicate. M denotes
monocistronic vector while B denotes bicistronic vector
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found that CHO-UCOE-B (Fig. 2c) had a higher
number of transfectomas with intensities of between
2 9 106 and 4 9 106 FU compared to that of CHO-
UCOE-M (Fig. 2b). In fact, CHO-UCOE-B had 6
clones with a sum of total intensities greater than
4 9 106 FU.
A total of 90, 27 and 122 monoclonal transfectomas
of NS0-pFUSE-M, CHO-UCOE-M and CHO-UCOE-
B, respectively, were isolated, scaled-up and evaluated
for H1C2 productivity using quantitative ELISA at
passage 10. Clones were categorized based on their
productivity: (1) non-producers if the productivity was
less than 1.0 lg/ml (2) low producers if productivity
was between 1.0–10.0 lg/ml (3) average producers if
it was between 10.0–50.0 lg/ml and (4) high produc-
ers if it was above 50.0 lg/ml.
At passage 10, almost half of the NS0-pFUSE-M
clones were non-producers and the remaining NS0-
pFUSE-M (54.2 %) clones were all low producers
(Fig. 3). In contrast, for the CHO-UCOE-M clones,
35.7 % were high producers, 50.0 % were low
producers and 14.3 % were non-producers, while for
the CHO-UCOE-B clones the numbers were 40.5 %
high producers, 27.9 % moderate producers, 24.1 %
low producers and 7.5 % non-producers.
Quantitative ELISA performed also showed that
the highest productivity of NS0-pFUSE-M clones was















Fig. 1 Qualitative ELISA of antibiotic resistant parental
transfectomas. All viable transfectomas were analyzed for
H1C2 productivity. All transfections in triplicate had 3 viable
clones each except for the parental NS0 cell transfected with
unlinearized pFUSE vectors, which had only 1 (transfectoma 2)
viable parental clone. Cells were considered low-producing if
the absorbance value was below 0.2 units. Although all CHO-
UCOE-M were viable, two of the transfectomas (transfectoma 1
and 3) were low producers
a b c
0.5 x 105 2 x106
0

















Fig. 2 Dot-blot analysis of transfectomas using ClonePix FL
system: Sum of total intensity (FU). From the fluorescence data
whereby each colored dot represents one monoclonal transfec-
toma, NS0 cells transfected with linearized pFUSE vector a had
lower fluorescence intensity compared to CHO cells transfected
with either monocistronic b and bicistronic c UCOE vectors.
Yellow dots and blue dots represent the isolated and non-isolated
transfectomas, respectively. (Color figure online)
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high producers of CHO-UCOE-M and CHO-UCOE-B
clones were between 50–110 lg/ml. No significant
difference in H1C2 mAb productivities were found
between CHO-UCOE-M and CHO-UCOE-B trans-
fectomas, but productivities of both CHO-UCOE-M
and CHO-UCOE-B transfectomas were at least 100
times higher than that of NS0-pFUSE-M transfecto-
mas. A cell-based ELISA (Dharshanan et al. 2011b)
also confirmed that H1C2 mAbs secreted by NS0-
pFUSE-M, CHO-UCOE-M and CHO-UCOE-B were
all able to bind to the C2-antigen expressed on the
surface of colorectal cancer cells with similar affinity
to our previously developed H1C2 mAbs.
Discussion
In a previous publication (Dharshanan et al. 2012) we
have compared the functionality and immunogenicity
of humanized mAbs prepared from mouse IgG against
the C2 antigen using a deimmunization method and a
logical substitution method. We came to the conclu-
sion that the deimmunization method was superior as
the resulting mAbs had lower immunogenicity when
tested in monkeys.
In those experiments, the humanized mAbs were
prepared by site-specific overlapping mutagenesis in
order to perform specific conversion of mouse residues
to the corresponding human residues. However, this
procedure is time consuming and relatively inefficient.
Therefore we decided to employ the direct substitution
of synthetically constructed DNA sequences with the
corresponding human residues instead. We inserted
the synthetic DNA into two different expression
systems (pFUSE & UCOE) which were transfected
into NS0 and CHO cells, and transfectoma viability
and productivity of H1C2 mAb were compared.
From our data we found that the use of UCOE vector
in CHO cells were consistent in generating high mAb-
producing stable cells. The other combinations,
pFUSE in NS0 cells, pFUSE in CHO cells and UCOE
in NS0 cells either did not produce viable cells or had
lower efficacy in producing cells that secreted high
levels of mAb. We also concluded that for production
of humanized anti-C2 mAb the use of bicistronic
UCOE vector to transfect CHO cells had the greatest
efficacy in generating large numbers of high producing
transfectomas.
The transfection of NS0 cells with linearized
pFUSE vectors resulted in all parental cell lines being
viable after antibiotic selection, whereas with unlin-
earized vectors only one viable parental cell line was
obtained. This could be due to the possibility that, after
entering the cell, the unlinearized vectors might be
cleaved non-specifically at random sites which could
cause the antibiotic resistance gene or the antibody
gene of interest to be destroyed, thus affecting cell
viability and antibody production. On the other hand,
linearization of the vector DNA before transfection by
a single digestion with a selected restriction enzyme in
a non-coding area of the gene may have the advantage
of ensuring the integrity of all necessary gene elements
of the vector, hence improving the survival and
productivity of the transfectomas in selective medium
(Stuchbury and Mu¨nch 2010).
The transfection of pFUSE vector into NS0 cells,
even when successful, generally resulted in lower
numbers of high producers than transfection of UCOE
vector in CHO cells. This could be due to the
possibility that the transgenes were inserted into
regions that suppressed their expression. The integra-
tion of a transgene into, or close to, heterochromatin
will result in it being silenced, whereas integration into
actively transcribed euchromatin usually leads to
transgene expression (Kwaks and Otte 2006). Because
a large proportion of the genome is in the form of
Fig. 3 Quantitative ELISA of monoclonal high-producer
transfectomas isolated using ClonePix FL system. A total of 90,
27 and 122 of the high-producing clones from each transfectoma
were isolated, scaled-up and after 10 passages, were evaluated for
their stability and productivity. By this passage approximately
45.8 % of the NS0-pFUSE-M were no longer producing H1C2
mAbs (\0.1 lg/ml) and the remaining clones were low producers
(0.1–10.0 lg/ml). For CHO-UCOE-M, 14.3 % were non-pro-
ducers, 50.0 % low producers and 35.7 % high producers
([50.0 lg/ml). For CHO-UCOE-B, 7.5 % were non-producers,
24.1 % low producers, 27.9 % moderate producers
(10.0–50.0 lg/ml) and 40.5 % high producers
Cytotechnology (2014) 66:625–633 631
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heterochromatin and insertion is random, the chance
of a transgene integrating into, or close to, hetero-
chromatin is high and the chance that the gene is
silenced is also high.
Successful transfection of UCOE vectors into CHO
was much more effective in generating high producer
cells. One reason could be due to the fact that UCOE
vectors contain ubiquitous chromatin opening ele-
ments. Ubiquitous chromatin opening elements are
elements derived from the promoters of housekeeping
genes which are usually transcriptionally active owing
to a significant extent of histone acetylation. There-
fore, employment of UCOE elements-incorporated
expression vectors was reported to give major
improvements in gene expression in stably-transfected
mammalian cells. This is thought to be through
UCOE’s effects on the structure of chromatin, pre-
venting transgene silencing and giving consistent,
stable and high-level gene expression irrespective of
the chromosomal integration site (Benton et al. 2002).
This is shown to be the case in the UCOE transfected
CHO cells in this study which has been shown to
generate higher numbers of high producer cells
secreting the humanized anti-C2 mAb compared to
pFUSE vectors.
However, there is a difference in the effective-
ness of monocistronic and bicistronic UCOE vec-
tors in producing CHO transfectomas that secrete
H1C2 mAb. Transfection of CHO cells with
monocistronic UCOE vectors and selection with
antibiotic resulted in all parental transfectomas
being viable, but only one population produced
significant levels of antibody as detected by
ELISA. On the other hand, all of the transfections
using bicistronic UCOE generated viable parental
transfectomas that produced significant levels of
antibody.
One explanation could be that when monocistronic
UCOE vectors were employed, two separate vectors
were transfected at the same time, one coding for the
light chain (pAS-hVL-hCL) of the antibody and one
for the heavy chain (pAS-hVH-hCH). Thus, cells
could be predominantly transfected with either pAS-
hVL-hCL (which would produce only the light chain
that is secreted) or pAS-hVH-hCH (which would
produce only the heavy chain that is not secreted) or
with both vectors (which would produce the whole
antibody that is secreted). Since both vectors contain
the same (puromycin) resistance gene all cells
successfully transfected with any one of or both
vectors would be viable after selection with puromy-
cin. This would give rise to viable cells that produced
light chains, heavy chains or whole antibody. As the
capture antibody used for detection of secreted H1C2
mAb in the medium was directed towards the Fc
region (whole antibody), results would therefore be
positive for populations of cells that predominantly
produced the whole antibody and negative for those
producing predominantly the light chain or heavy
chain (Mateo et al. 1997). Ideally, different selection
antibiotics should be used for each of the monocis-
tronic vectors during co-transfection.
After selection and cloning the production rate of
antibodies in a substantial number of clones fell, more
in NS0 transfectomas and less in CHO transfectomas.
This fall in production in NS0 transfectomas could be
due to the fact that large genomic re-arrangements had
occurred during amplification. This instability of a
transfectoma may involve the silencing of the exog-
enous gene due to modifications such as methylation
of CpG DNA sequences (Zhang et al. 2010), histone
deacetylation and chromatin condensation (Kim et al.
2011) thus resulting in loss of high-producing clones.
This phenomenon may have occurred more frequently
in NS0 cells transfected with pFUSE vectors than in
CHO cells transfected with UCOE vectors.
However, the reason why H1C2 mAb could not be
expressed in NS0 cells using UCOE vectors or in CHO
cells using pFUSE vectors could not be determined
and warrants further investigation. To our knowledge,
H1C2 mAbs have previously been only produced
using NS0 cells and this will be the first time this
antibody is produced in CHO cells which are preferred
over NS0 cells (Cacciatore et al. 2010). We feel that
the procedure of transfecting CHO with UCOE vector
is more advantageous in the industrial production of
these humanized H1C2 mAb and may serve as a
general template for production of other mAbs.
Conclusion
From the experiments described in this article several
conclusions may be drawn. First, the use of synthetic
DNA coding the variable regions of H1C2 mAb
provides a convenient and fast route to develop H1C2
mAbs which remain functional. Second, irrespective
of the vector DNA size, the linearization of vectors
632 Cytotechnology (2014) 66:625–633
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increases the transfection efficiency; however the
restriction enzyme must be chosen with careful
consideration. Third, pFUSE expression vectors work
well in NS0 cells and UCOE expression vectors work
well in CHO cells. Fourth, it is advisable to use two
different selection antibiotics for co-transfection per-
formed using two monocistronic vectors, in order to
minimize the probability of obtaining transfectomas
expressing only the light chain of the antibody.
Finally, transfection of CHO cells with UCOE vectors
was more effective in generating a greater number of
high-producing and stable clones, making it much
easier and faster to find clones with the high produc-
tivity and stability required for manufacturing. In
addition, this is the first time H1C2 mAb has been
expressed in CHO cells which is the preferred cell line
in manufacturing. Therefore these H1C2 mAbs could
now be conveniently produced at large-scale at a
reduced cost.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use,
distribution, and reproduction in any medium, provided the
original author(s) and the source are credited.
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